Betz Stephen F. 4

What Happened

• Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals (CRNX), sold a total of 10,612 shares in two open‑market transactions on March 16, 2026, generating aggregate proceeds of approximately $396,611. The sales were: 6,371 shares at a VWAP of $37.11 for $236,428 and 4,241 shares at a VWAP of $37.77 for $160,183. These dispositions were done pursuant to broker instructions under a Rule 10b5‑1 trading plan and were reported as tax‑withholding sales related to vested restricted stock units.

Key Details

• Transaction date: March 16, 2026 (Form 4 filed March 18, 2026 — filed timely)
• Sales: 6,371 shares @ VWAP $37.11 (price range $36.42–$37.38); 4,241 shares @ VWAP $37.77 (price range $37.42–$38.23)
• Total shares sold: 10,612; total proceeds ≈ $396,611
• Footnotes: F1 — sales effected to cover tax withholding on RSU vestings (grants from 2022–2025) and executed under a Rule 10b5‑1 plan; F2/F3 — VWAPs and intraday price ranges provided
• Shares owned after transaction: Not provided in the supplied data

Context

• These were routine disposition transactions to satisfy tax withholding on vested RSUs, not open-market purchases; such sales are commonly administrative and do not by themselves indicate insider sentiment. Transactions were executed under a pre-established 10b5‑1 plan, which schedules trades according to predetermined rules.